Dyslipidemia and type 2 diabetes mellitus;Dyslipidémie et diabète sucré de type 2

Louvain Medical

Volumn 126, Issue 5, 2007, Pages 121-127

  Kherroubi, M ^b   Buysschaert, M ^c   Pollak, Felipe ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b Hôpital Militaire Universitaire d'Oran   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

ARTICLE; CARDIOVASCULAR DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DYSLIPIDEMIA; GLYCEMIC CONTROL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIMARY PREVENTION; SECONDARY PREVENTION; UNITED KINGDOM;

EID: 34347352077     PISSN: 00246956     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Haffner S, Letho S, Ronnemma T et al.: Mortality from coronary heart disease in subjects with type 2. Diabetes and in non diabetic subjects with prior myocardial infarction. N.Engl.J.Med. 1998; 339: 229-234.
2. Whiteley L, Padmanabhan S, Hole D, Isles C: Should Diabetes be considered a Coronary Heart Disease Risk Equivalent ? Results from 25 years of follow-up in the Renfrew and Paisley Survey. Diabetes Care. 2005; 28 : 1588-1593.
3. Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Type 2 Diabetes as a Coronary Heart Disease Equivalent. A 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005; 28 : 2901-2907.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 Diabetes. Lancet. 1998; 317: 703-711.
5. Turner RC, Millns H, Neil HA, Stratton IM et al.: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS : 23). BMJ. 1998; 316 (7134): 823-828.
6. Siegel RD, Cupples A, Schaefer EJ, Wilson PW: Lipoproteins, apolipoproteins and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism. 1996; 45(10): 1267-1272.
7. Steiner G: Dyslipoproteinemias of Diabetes. Atherosclerosis. 1994; 110: S27-33.
8. Ziegler O, Guerci B, Candiloros H, Drouin P: Lipoprotein (a) and diabetes mellitus. Diabetes Metab. 1995; 21(2): 127-138.
9. de Vries R, Perton FG, Dallinga-Thie GM, van Roon AM et al.: Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and non diabetic subjects: role of CETP and triglycerides. Diabetes. 2005; 54(12): 3554-3559.
10. Kolovou GD, Anagnostopoulou KK, Cokkinos DV: Pathophysiology of dyslipidemia in the metabolic syndrome. Postgrad Med. 2005; 81: 358-366.
11. Koskinen P, Manttari M, Manninen V, Huttunen JK et al.: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992; 15(7):820-825.
12. Rubins HB, Robins SJ, Collins D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. Veteran's Affair High Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) Study Group. N.Engl.Med. 1999; 341: 410-418.
13. Steiner G and the Diabetes Atherosclerosis Intervention Study (DAIS): Effect of Fenofibrate on progression of coronary artery disease in type 2 diabetes. A randomized study. Lancet. 2001; 357: 905-910.
14. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9765 people with type 2 diabetes mellitus (the FIELD study) : randomized controlled trial. Lancet. 2005; 366: 1849-1861.
15. Costa J, Borges M, David C, Vaz Carneiro A: Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised trials. BMJ. 2006; 332(7550): 1115-1124.
16. Goldberg R, Mellies M, Sacks F et al.: Cardiovascular events and their reduction with Pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels: subgroup analysis in The Cholesterol and Recurrent Events (CARE) trial. Circulation. 1998; 98: 2513-519.
17. Pyorala K, Pedersen Tr, Kjekhus J, et al. and the Scandinavian Simvastatin Survival Study (4S) Group: Cholesterol lowering with Simvastatin improves prognosis of diabetic patients with coronary heart disease : A subgroup analysis of the 4S study. Diabetes Care. 1997; 20: 614-620.
18. Collins R, Armitage J, Parish S, Sleigh P, Peto R and Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with Simvastatin in 5963 people with diabetes : a randomised placebo-controlled trial. Lancet. 2003; 361: 2005-2014.
19. Colhoun HM, Betteridge DJ, Durrington PN, Hitmann GA and the CARDS study investigators: Primary prevention of cardiovascular disease with Atorvastatin in type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004; 364: 685-696.
20. Third report of the National Cholesterol Education Program (NCEP) on the detection, evaluation and treatment of high blood cholesterol in adult (ATP III). Executive summary. NIH publication 01-3670, May 2001. (www.nhlbi.nih.gov/ guidelines/cholesterol/)
21. American Diabetes Association: Management of dyslipidemia in adults with Diabetes. Diabetes Care. 2003; 26: S83-86.
22. Debacker G: European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiov Prev Rehab. 2003; 10:S1-S78.
23. Grundy S, Cleeman J et al. for the Coordinating Committee of the National Cholesterol Education program: Implications of recent Clinical Trials for the National Education Program Adult Treatment Panel III Guidelines. Circulation. 2004; 110: 227-239.
24. Sheperd J, Barter P, Carmena R et al. for the Treating to new Targets Investigators: Effect of lowering LDL Cholesterol substantially below currently recommended levels in patients with Coronary Heart Disease and Diabetes. The Treating to New Targets (TNT) study. Diabetes Care. 2006; 29: 1220-1226.
25. Dunn FL: Management of hyperlipidemia on diabetes mellitus. Endocrinol Metab Clin North Am. 1992; 21(2):395-414.
26. Buse JB, Tan MH, Prince MJ, Erickson PP: The effects of oral anti-hyperglycemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab. 2004; 6(2): 133-156.
27. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352(9131): 854-865.
28. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E et al. (PROactive investigators): Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular events): a randomized controlled trial. Lancet. 2005; 366: 1279-1289.
29. American Diabetes Association. Nutrition Recommendations and Interventions for Diabetes-2006 (position statement). Diabetes Care. 2006; 29(9): 2140-2157.
30. http://inami.fgov.be/drugs/fr/drugs/hypolipidemiants/index.htm
31. Athyros VG, Papageorgiou AA et al.: Atorvastatin and micronized Fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 2002; 25: 1198-1202.
32. Malcolm Law, Alicja R. Rudnicka: Statin Safety: A Systematic Review. Am Journal of Cardiology. 2006; 97(8): S52-60.
33. Brown BG, Zhao XQ, Chait A et al. : Simvastatin and Niacin, antioxidant vitamins, or the combination for the prevention of Coronary Disease. N Engl J Med. 2001; 345: 1538-1539.
34. Gaede P, Pemille V et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N.Engl.J.Med. 2003; 248: 383-393.
35. Freeman D, Norrie J, Sattar N et al.: Pravastatin and the development of Diabetes Mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001; 103: 357-362.
36. Douglas K, O'Malley PG, Jackson JL: Meta-analysis: the effect of statins on albuminuria. Ann Intern Med. 2006;145(2):117-124.